Aktienanalyse zu Freenome, Inc. Common stock (FRNM)FRNMFreenome, Inc. Common stock

Freenome, Inc. is an early cancer detection company developing blood-based screening tests to identify cancer. The Company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. The Company's development of SimpleScreen CRC for colorectal cancer screening, with clinical validation through the PREEMPT CRC Study, and a pipeline of tests for lung cancer and additional indications is designed to increase cancer screening participation. SimpleScreen CRC is a colorectal cancer screening test that uses a blood sample to look for signs of cancer and certain precancerous growths. The Company's platform integrates multiomics, artificial intelligence and machine learning to uncover complex biological signals associated with cancer. It operates in the Healthcare sector.

Freenome, Inc. is a good buy right now due to its recent FDA approval for a colorectal cancer screening test, which has driven a 5% increase in stock price and indicates strong future revenue potential. The current price is $12.77, significantly below the analyst price target of $21, suggesting a potential upside of 64%. Additionally, the stock has shown a recent 5-day change of +8.68%, indicating positive momentum. However, a risk to consider is the negative net income reported for Q4 2025 at -740568.00 USD, which highlights ongoing financial challenges that could affect performance in the near term.